Intravenous Tramadol CRL Casts Shadow On Avenue’s Cipla Deal
Avenue 'Very Surprised' After Safety Concern Raised By FDA
Executive Summary
Avenue’s two-stage deal with an arm of Cipla faces uncertainty following a US Complete Response Letter for its intravenous tramadol. The US firm says it is "very surprised" with the potential safety concern raised and plans to seek a meeting with the agency at the earliest to resolve the issue.
You may also be interested in...
Keeping Track: Gavreto, Sogroya Bring Annual CDER Novel Approvals To 40; New Analgesic Products Make It Past US FDA
The latest drug approval news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Cyber-Attacked Dr Reddy’s Keeps Eye On Sputnik Plans
Dr Reddy’s management clears air on ransomware attack and says all critical operations are being enabled in a 'controlled and cautious' manner. The Indian firm also shared a timeline for its partnered Russian COVID-19 vaccine amid a free supply chorus in India.
Cyberattacked Dr. Reddy’s Keeps Eye On Sputnik Plans
Dr Reddy’s management clears air on ransomware attack and says all critical operations are being enabled in a 'controlled and cautious' manner. The Indian firm also shared a timeline for its partnered Russian COVID-19 vaccine amid a free supply chorus in India.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: